Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
7
Bullish
2
Bearish
20
Neutral
7
Bullish
19
Bearish
15
Neutral
0
Bullish
17
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics.
Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market.
The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans.
With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products.
Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
31,123 Cr
Low Risk
33.7
34.2
1.2
6.3
1,770.05
950.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Emcure Pharmaceuticals Ltd (EMCURE) is currently trading at 1,635.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics. Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market. The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans. With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products. Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹950.00 and a high of ₹1,770.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Emcure Pharmaceuticals Ltd has a market capitalization of approximately 31,123.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.67 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 31,123.02 Cr, Emcure Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Emcure Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 33.67. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Emcure said it in-licensed Lenacapavir from Gilead Life Sciences for India and emerging markets, calling it a major development that strengthens its ARV portfolio.
The decline was attributed to profit booking after the earnings announcement, even though the company reported higher profit and revenue.
The stock fell about 3% after large block deals led to selling pressure, with around 40.6 lakh shares (about 2.4% equity) changing hands.
Poviztra is a brand of semaglutide injection for weight management, marketed by Emcure in India. Its price was cut by up to 55% to make it more affordable and accessible, responding to increased competition from generic drugs.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2895.85 | 37,883 Cr | 35.87 | 8.37 | 0.00 | 23.33 | 29.09 | 17.16 | ||
2145.90 | 34,551 Cr | 45.84 | 9.08 | 0.70 | 18.88 | 25.16 | 16.00 | ||
1750.35 | 31,377 Cr | 37.04 | 3.28 | 0.95 | 8.27 | 12.46 | 7.18 | ||
1679.95 | 31,123 Cr | 33.67 | 6.29 | 0.00 | 18.67 | 21.76 | 9.79 | ||
1348.20 | 26,111 Cr | 122.59 | 5.29 | 0.00 | 5.75 | 7.39 | 2.31 | ||
159.80 | 23,893 Cr | -73.31 | 2.93 | 0.00 | -3.58 | 2.58 | -1.81 | ||
947.50 | 23,653 Cr | 71.04 | 10.42 | 0.00 | 12.62 | 16.34 | 9.99 | ||
| Median: 7 Co. | — | 1679.95 | 31,123 Cr | 37.04 | 6.29 | 0.00 | 12.62 | 16.34 | 9.79 |
Audited Financial Results
Emcure published extracts of audited consolidated and standalone results for Q4 and FY ended Mar 31, 2026 (newspapers: Financial Express, Loksatta) showing consolidated FY26 revenue ~Rs 92,035.40 mn and PBT ~Rs 12,871.43 mn; standalone FY26 revenue ~Rs 52,431.88 mn and PBT ~Rs 9,441.91 mn; results approved by Board on May 5, 2026 and uploaded to company website.
Audited financial results
Emcure Pharmaceuticals published newspaper extracts of audited consolidated and standalone financial results for the quarter and year ended Mar 31, 2026 (Board approved May 5, 2026) and uploaded the extracts to its website.
Director Re-appointment
Emcure's Board (May 5, 2026) approved re-appointment of Dr. Mukund Gurjar as Whole-time Director for 1 year from Aug 28, 2026 and Mr. Satish Mehta as Managing Director for 5 years from Apr 1, 2027, subject to shareholder approval.
Management Re-appointments
Board (May 5, 2026) approved re-appointment of Mr. Satish Mehta as Managing Director for 5 years from April 1, 2027 and Dr. Mukund Gurjar as Whole-time Director for 1 year from August 28, 2026, both subject to shareholder approval.
Earnings Presentation
Emcure released audited consolidated and standalone Q4/FY26 results: FY26 revenue ₹9,204 Cr (+16.6%, crossed US$1bn), Adj. PAT +40.9%, EBITDA margin expansion, driven by strong international growth, M&A and partnerships.
Earnings Presentation
Emcure published audited consolidated and standalone Q4/FY26 results: revenue ₹9,204 Cr (crossed US$1bn) up 16.6% YoY, international revenue +22%, EBITDA margin 19.4% (+83bps), Adj. PAT +40.9% — results above guidance.
